Latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma – Pipeline Review, H1 2018, provides an overview of the Non-Hodgkin Lymphoma pipeline landscape.
Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Hodgkin Lymphoma pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are:- 10, 4, 30, 160, 136, 1, 5, 126, 15 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 19, 22, 17 and 4 molecules, respectively.
Non-Hodgkin Lymphoma pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies Mentioned in Non-Hodgkin Lymphoma are: 3SBio Inc, 4SC AG, AB Science SA, AbbVie Inc, ACEA Biosciences Inc, Actinium Pharmaceuticals Inc, ADC Therapeutics SA, Affimed GmbH, Affitech A/S, Agios Pharmaceuticals Inc, Aileron Therapeutics Inc, AlfaSigma SpA, Allinky Biopharma, Altor BioScience Corp, Amgen Inc, Angimmune LLC, Aptevo Therapeutics Inc, arGEN-X BV, Ariad Pharmaceuticals Inc, ArQule Inc, Arrien Pharmaceuticals LLC, Arven Ilac, Asana BioSciences LLC, Aslan Pharmaceuticals Pte Ltd, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, Autolus Ltd, Bantam Pharmaceutical LLC, Bayer AG, BeiGene Ltd, Bellicum Pharmaceuticals Inc, Bio-Path Holdings Inc, Biocon Ltd, Biogen Inc, BioInvent International AB, BioLineRx Ltd, BioSight Ltd, Biothera Pharmaceutical Inc, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Brickell Biotech Inc, Bristol-Myers Squibb Co, Calithera Biosciences Inc, CARsgen Therapeutics Ltd, CBT Pharmaceuticals Inc, Celgene Corp, Cell Medica Ltd, Cell Source Inc, Cell>Point LLC, Celldex Therapeutics Inc, Cellectar Biosciences Inc, Cellectis SA, Celleron Therapeutics Ltd, Cellestia Biotech AG, Celltrion Inc, Cellular Biomedicine Group Inc, Centrose LLC, Cerenis Therapeutics Holding SA, CerRx Inc, Chipscreen Biosciences Ltd, Cielo Therapeutics Inc, Clevexel Pharma SAS, Corvus Pharmaceuticals Inc, CrystalGenomics Inc, CSPC Pharmaceutical Group Limited, CTI BioPharma Corp, Curis Inc, Cyclacel Pharmaceuticals Inc, CytomX Therapeutics Inc, Daiichi Sankyo Co Ltd, Debiopharm International SA, Denovo Biopharma LLC, Dynavax Technologies Corp, eFFECTOR Therapeutics Inc, Eisai Co Ltd, Eli Lilly and Co, Epizyme Inc, Erytech Pharma SA, Eureka Therapeutics Inc, Evotec AG, F. Hoffmann-La Roche Ltd, Forma Therapeutics Inc, Formula Pharmaceuticals Inc, Forty Seven Inc, Fujifilm Holdings Corporation, Galderma SA, Gamida Cell Ltd, Genentech Inc, Genor BioPharma Co Ltd, Genosco Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Grupo Ferrer Internacional SA, GT Biopharma Inc, H3 Biomedicine Inc, Heidelberg Pharma AG, Hualan Biological Engineering Inc, Hutchison MediPharma Ltd, IGF Oncology LLC, Ignyta Inc, Immune Design Corp, ImmunGene Inc, ImmunoGen Inc, Immunomedics Inc, Immunomet Therapeutics Inc, Immunovaccine Inc, Incyte Corp, Inflection Biosciences Ltd, Innate Pharma SA, Innovent Biologics Inc, IO Biotech ApS, Japan Tobacco Inc, JHL Biotech Inc, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, K-Stemcell Co Ltd, KAHR medical Ltd, Kainos Medicine Inc, Karyopharm Therapeutics Inc, Kiromic Inc, Kite Pharma Inc, Klyss Biotech Inc, Komipharm International Co Ltd, Kyowa Hakko Kirin Co Ltd, Leadiant Biosciences Inc, Les Laboratoires Servier SAS, LFB SA, Loxo Oncology Inc, LSK BioPartners Inc, Mabion SA, MacroGenics Inc, Meabco AS, MedImmune LLC, Medivir AB, MEI Pharma Inc, MENTRIK Biotech LLC, Merck & Co Inc, Merck KGaA, Millennium Pharmaceuticals Inc, Miltenyi Biotec GmbH, Miragen Therapeutics Inc, Mirati Therapeutics Inc, Mitsubishi Tanabe Pharma Corp, Molecular Templates Inc, Moleculin Biotech Inc, Morphogenesis Inc, MorphoSys AG, NantKwest Inc, NBE-Therapeutics AG, Nerviano Medical Sciences Srl, Neumedicines Inc, Nichi-Iko Pharmaceutical Co Ltd, Nordic Nanovector ASA, NovaLead Pharma Pvt Ltd, Novartis AG, NovImmune SA, Oncobiologics Inc, Onconova Therapeutics Inc, Oncopeptides AB, Oncovir Inc, Oncternal Therapeutics Inc, Ono Pharmaceutical Co Ltd, Onxeo SA, Oxford BioTherapeutics Ltd, Patrys Ltd, Pfizer Inc, Pharma Mar SA, Philogen SpA, PIQUR Therapeutics AG, Plexxikon Inc, Portola Pharmaceuticals Inc, Prescient Therapeutics Ltd, Protheragen Inc, Quimatryx SL, Rafael Pharmaceuticals Inc, Refuge Biotechnologies Inc, Regeneron Pharmaceuticals Inc, Respiratorius AB, Rhizen Pharmaceuticals SA, Richter Gedeon Nyrt, Sandoz International GmbH, Sanofi, Sareum Holdings Plc, Seattle Genetics Inc, Selvita SA, Senhwa Biosciences Inc, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, Shanghai Henlius Biotech Co Ltd, Shanghai Pharmaceutical Co Ltd, Shenzhen Salubris Pharmaceuticals Co Ltd, Sierra Oncology Inc, Solasia Pharma KK, Soligenix Inc, Spectrum Pharmaceuticals Inc, Stemline Therapeutics Inc, Sunesis Pharmaceuticals Inc, Supratek Pharma Inc, Surface Oncology Inc, Sutro Biopharma Inc, Syndax Pharmaceuticals Inc, TaiGen Biotechnology Co Ltd, Taiho Pharmaceutical Co Ltd, Taiwan Liposome Company Ltd, Takara Bio Inc, TCR2 Therapeutics Inc, Teva Pharmaceutical Industries Ltd, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Transgene Biotek Ltd, Transgene SA, Trillium Therapeutics Inc, Triphase Accelerator Corp, Trovagene Inc, TTY Biopharm Company Ltd, United BioPharma Inc, Unum Therapeutics Inc, Verastem Inc, Vivolux AB, Vyriad Inc, Xencor Inc, Zhejiang Hisun Pharmaceutical Co Ltd, ZIOPHARM Oncology Inc
Request for a Sample Copy of this Research Report at: https://www.marketinsightsreports.com/reports/0926874987/non-hodgkin-lymphoma-pipeline-review-h1-2018/inquiry?source=apexnews&Mode=01
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma.
2. The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources.
3. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
4. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
5. The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma therapeutics and enlists all their major and minor projects.
6. The pipeline guide evaluates Non-Hodgkin Lymphoma therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
7. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
8. The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma
Reasons to buy this Report:
1. procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
2. Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma.
Classify potential new clients or partners in the target demographic.
3. Develop tactical initiatives by understanding the focus areas of leading companies.
4. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
5. Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics.
6. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
7. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Important Points Covered In Table of Content are:
Therapeutics Assessment, Assessment by Target, Assessment by Mechanism of Action, Assessment by Route of Administration, Assessment by Molecule Type, Pipeline Overview, Pipeline by Companies, Pipeline by Universities/Institutes, Products under Development by Companies, Products under Development by Universities/Institutes.